153 related articles for article (PubMed ID: 23052274)
1. [Prostate carcinoma with squamous differentiation after combination endocrine therapy: a case report].
Nagashima T; Niiro M; Hirayama K; Date S; Okihara K; Mukaisho K
Hinyokika Kiyo; 2012 Aug; 58(8):457-60. PubMed ID: 23052274
[TBL] [Abstract][Full Text] [Related]
2. Does small-cell phenotype predict the natural history of prostate cancer? A case study in disease behavior.
Slovin SF
Nat Clin Pract Oncol; 2007 Sep; 4(9):551-4. PubMed ID: 17728713
[TBL] [Abstract][Full Text] [Related]
3. Safe usage of bicalutamide and goserelin in a male patient with acute intermittent porphyria and prostate cancer.
Sofie Lichtwarck Bjugn F; Storjord E; Kristensen RM; Brekke OL
Scand J Urol; 2019; 53(2-3):171-173. PubMed ID: 30714461
[No Abstract] [Full Text] [Related]
4. Volumetric-modulated arc therapy for a pelvic lymph node metastasis from prostate cancer: a case report.
von Eyben FE; Kangasmäki A; Kiljunen T; Joensuu T
Tumori; 2013; 99(3):e120-3. PubMed ID: 24158080
[TBL] [Abstract][Full Text] [Related]
5. Effect of total androgen ablation on pathologic stage and resection limit status of prostate cancer. Initial results of the Italian PROSIT study.
Montironi R; Diamanti L; Santinelli A; Galetti-Prayer T; Zattoni F; Selvaggi FP; Pagano F; Bono AV
Pathol Res Pract; 1999; 195(4):201-8. PubMed ID: 10337657
[TBL] [Abstract][Full Text] [Related]
6. [Successful combined treatment with maximal androgen blockade (MAB), intra arterial chemotherapy and radiation for advanced prostatic ductal adenocarcinoma : report of two cases].
Nishihara C; Kuratsukuri K; Tanaka T; Kawashima H; Nakatani T
Hinyokika Kiyo; 2011 Apr; 57(4):209-12. PubMed ID: 21646853
[TBL] [Abstract][Full Text] [Related]
7. [A case of locally advanced prostate cancer with low serum testosterone associated with intake of an androgenic medicine].
Sakura M; Tsukamoto T; Yonese J; Nakaishi M; Maezawa T; Takimoto K; Fukui I
Nihon Hinyokika Gakkai Zasshi; 2003 May; 94(4):529-32. PubMed ID: 12795169
[TBL] [Abstract][Full Text] [Related]
8. [PRIMARY SQUAMOUS CELL CARCINOMA OF THE PROSTATE: A CASE REPORT].
Fukui K; Nagasawa S; Hanasaki T; Ueda Y; Aihara K; Kokura K; Matsuo S; Zozumi M; Tsukamoto Y
Nihon Hinyokika Gakkai Zasshi; 2019; 110(2):129-133. PubMed ID: 32307381
[TBL] [Abstract][Full Text] [Related]
9. Prostate-cancer-specific survival and clinical progression-free survival in men with prostate cancer treated intermittently with testosterone-inactivating pharmaceuticals.
Scholz M; Lam R; Strum S; Jennrich R; Johnson H; Trilling T
Urology; 2007 Sep; 70(3):506-10. PubMed ID: 17905106
[TBL] [Abstract][Full Text] [Related]
10. Chemical castration and anti-androgens induce differential gene expression in prostate cancer.
Lehmusvaara S; Erkkilä T; Urbanucci A; Waltering K; Seppälä J; Larjo A; Tuominen VJ; Isola J; Kujala P; Lähdesmäki H; Kaipia A; Tammela TLj; Visakorpi T
J Pathol; 2012 Jul; 227(3):336-45. PubMed ID: 22431170
[TBL] [Abstract][Full Text] [Related]
11. [Brainstem metastasis from a prostate adenocarcinoma in the context of Muir-Torre syndrome].
Aldave G; Pay E; Queipo F; Idoate MA; Guridi J
Neurocirugia (Astur); 2013; 24(2):78-81. PubMed ID: 23177734
[TBL] [Abstract][Full Text] [Related]
12. [Giant prostate carcinoma treated effectively with endocrine therapy: case report].
Masue N; Hasegawa Y
Hinyokika Kiyo; 2007 Feb; 53(2):133-5. PubMed ID: 17352166
[TBL] [Abstract][Full Text] [Related]
13. A Phase II, Randomized, Open-Label Study of Neoadjuvant Degarelix versus LHRH Agonist in Prostate Cancer Patients Prior to Radical Prostatectomy.
Sayyid RK; Evans A; Hersey K; Maloni R; Hurtado-Coll A; Kulkarni G; Finelli A; Zlotta AR; Hamilton R; Gleave M; Fleshner NE
Clin Cancer Res; 2017 Apr; 23(8):1974-1980. PubMed ID: 27756786
[No Abstract] [Full Text] [Related]
14. Degarelix Versus Goserelin Plus Bicalutamide in the Short-Term Relief of Lower Urinary Tract Symptoms in Prostate Cancer Patients: Results of a Pooled Analysis.
Mason M; Richaud P; Bosnyak Z; Malmberg A; Neijber A
Low Urin Tract Symptoms; 2017 May; 9(2):82-88. PubMed ID: 28394498
[TBL] [Abstract][Full Text] [Related]
15. Cutaneous Metastases From Adenocarcinoma of the Prostate.
Flores-Terry MÁ; Cruz-Conde de Boom R; García-Arpa M; de Lara-Simón IM
Actas Dermosifiliogr (Engl Ed); 2018 May; 109(4):360. PubMed ID: 28823393
[No Abstract] [Full Text] [Related]
16. Metastatic prostatic adenocarcinoma mimicking inflammatory breast carcinoma: a case report.
Njiaju UO; Truica CI
Clin Breast Cancer; 2010 Feb; 10(1):E3-5. PubMed ID: 20133250
[TBL] [Abstract][Full Text] [Related]
17. [Reevaluation of MAB therapy and progress of endocrine therapy].
Klotz L; Payne H; Gillatt D; Keane T; Morris C; Akaza H; Hirao ; Akakura K; Fukagai T
Gan To Kagaku Ryoho; 2005 May; 32(5):705-28. PubMed ID: 15934164
[No Abstract] [Full Text] [Related]
18. Undetectable level of prostate specific antigen (PSA) nadir predicts PSA biochemical failure in local prostate cancer with delayed-combined androgen blockade.
Soga N; Arima K; Sugimura Y
Jpn J Clin Oncol; 2008 Sep; 38(9):617-22. PubMed ID: 18697759
[TBL] [Abstract][Full Text] [Related]
19. Androgen deprivation therapy for volume reduction, lower urinary tract symptom relief and quality of life improvement in patients with prostate cancer: degarelix vs goserelin plus bicalutamide.
Axcrona K; Aaltomaa S; da Silva CM; Ozen H; Damber JE; Tankó LB; Colli E; Klarskov P
BJU Int; 2012 Dec; 110(11):1721-8. PubMed ID: 22500884
[TBL] [Abstract][Full Text] [Related]
20. [Intermittent androgen deprivation treatment of prostate cancer restarted at low level of serum prostate specific antigen: a pilot study].
Maekawa S; Maegawa M; Ushida H; Inoue K; Kaneko Y; Ohmori K; Nishimura K
Hinyokika Kiyo; 2001 Aug; 47(8):553-5. PubMed ID: 11579594
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
